Prospective studies of pre- and post-operative MEK inhibition are required to develop and validate a multimodal treatment algorithm and to more comprehensively understand how medical therapy and surgical approaches may augment each other in the treatment of NF1-PN. This evidence concerns the gene MAP2K7 and poikiloderma with neutropenia.